T cell receptor binding affinity governs the functional profile of cancer-specific CD8+ T cells

Clinical and Experimental Immunology

Volumn 180, Issue 2, 2015, Pages 255-270

  Tan, M P ^a   Gerry, A B ^b   Brewer, J E ^b   Melchiori, L ^b   Bridgeman, J S ^a   Bennett, A D ^b   Pumphrey, N J ^b   Jakobsen, B K ^b   Price, D A ^a   Ladell, K ^a   Sewell, A K ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^b Adaptimmune Ltd   (United Kingdom)

Author keywords

Adoptive therapy; Cancer; T cell; T cell receptor; Tumour antigen

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; LENTIVIRUS VECTOR; LEUKOCYTE ANTIGEN; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; T LYMPHOCYTE ANTIGEN; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; LYMPHOCYTE ANTIGEN RECEPTOR; PEPTIDE; TUMOR ANTIGEN; TUMOR PROTEIN;

ARTICLE; CANCER CELL; CANCER GENE THERAPY; CD8+ T LYMPHOCYTE; CELL BASED GENE THERAPY; CONTROLLED STUDY; CROSS REACTION; CYTOKINE PRODUCTION; DRUG BINDING; DRUG HALF LIFE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HLA SYSTEM; HUMAN; HUMAN CELL; PHAGE DISPLAY; PRIORITY JOURNAL; RECEPTOR AFFINITY; SINGLE DRUG DOSE; T CELL CULTURE; T LYMPHOCYTE ACTIVATION; VIRAL GENE DELIVERY SYSTEM; GENETICS; IMMUNOLOGY; NEOPLASM; PATHOLOGY; TUMOR CELL LINE;

ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; PEPTIDES; RECEPTORS, ANTIGEN, T-CELL;

EID: 84927655865     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12570     Document Type: Article

References (78)

1. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol 2006; 24:175-208.
2. Cole DK, Pumphrey NJ, Boulter JM etal. Human TCR-binding affinity is governed by MHC class restriction. J Immunol 2007; 178:5727-5734.
3. Aleksic M, Liddy N, Molloy PE etal. Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategies. Eur J Immunol 2012; 42:3174-3179.
4. Savage PA, Davis MM. A kinetic window constricts the T cell receptor repertoire in the thymus. Immunity 2001; 14:243-252.
5. Marr LA, Gilham DE, Campbell JD, Fraser AR. Immunology in the clinic review series; focus on cancer: double trouble for tumours: bi-functional and redirected T cells as effective cancer immunotherapies. Clin Exp Immunol 2012; 167:216-225.
6. Kunert A, Straetemans T, Govers C etal. TCR-engineered T cells meet new challenges to treat solid tumors: choice of antigen, T cell fitness, and sensitization of tumor milieu. Front Immunol 2013; 4:363.
7. Morgan RA, Dudley ME, Wunderlich JR etal. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314:126-129.
8. Johnson LA, Morgan RA, Dudley ME etal. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009; 114:535-546.
9. Schmitt TM, Ragnarsson GB, Greenberg PD. T cell receptor gene therapy for cancer. Hum Gene Ther 2009; 20:1240-1248.
10. Robbins PF, Morgan RA, Feldman SA etal. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011; 29:917-924.
11. Parkhurst MR, Yang JC, Langan RC etal. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 2011; 19:620-626.
12. Hong JJ, Rosenberg SA, Dudley ME etal. Successful treatment of melanoma brain metastases with adoptive cell therapy. Clin Cancer Res 2010; 16:4892-4898.
13. Morgan RA, Chinnasamy N, Abate-Daga D etal. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 2013; 36:133-151.
14. Lagisetty KH, Morgan RA. Cancer therapy with genetically-modified T cells for the treatment of melanoma. J Gene Med 2012; 14:400-404.
15. Varela-Rohena A, Molloy PE, Dunn SM etal. Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nat Med 2008; 14:1390-1395.
16. McKeithan TW. Kinetic proofreading in T-cell receptor signal transduction. Proc Natl Acad Sci USA 1995; 92:5042-5046.
17. Stone JD, Chervin AS, Kranz DM. T-cell receptor binding affinities and kinetics: impact on T-cell activity and specificity. Immunology 2009; 126:165-176.
18. Laugel B, van den Berg HA, Gostick E etal. Different T cell receptor affinity thresholds and CD8 coreceptor dependence govern cytotoxic T lymphocyte activation and tetramer binding properties. J Biol Chem 2007; 282:23799-23810.
19. Bridgeman JS, Sewell AK, Miles JJ, Price DA, Cole DK. Structural and biophysical determinants of alphabeta T-cell antigen recognition. Immunology 2012; 135:9-18.
20. Wooldridge L, Lissina A, Cole DK, van den Berg HA, Price DA, Sewell AK. Tricks with tetramers: how to get the most from multimeric peptide-MHC. Immunology 2009; 126:147-164.
21. Laugel B, Boulter JM, Lissin N etal. Design of soluble recombinant T cell receptors for antigen targeting and T cell inhibition. J Biol Chem 2005; 280:1882-1892.
22. Whelan JA, Dunbar PR, Price DA etal. Specificity of CTL interactions with peptide-MHC class I tetrameric complexes is temperature dependent. J Immunol 1999; 163:4342-4348.
23. van den Berg HA, Ladell K, Miners K etal. Cellular-level versus receptor-level response threshold hierarchies in T-cell activation. Front Immunol 2013; 4:250.
24. Melenhorst JJ, Scheinberg P, Chattopadhyay PK etal. Detection of low avidity CD8+ T cell populations with coreceptor-enhanced peptide-major histocompatibility complex class I tetramers. J Immunol Methods 2008; 338:31-39.
25. Cole DK, Yuan F, Rizkallah PJ etal. Germ line-governed recognition of a cancer epitope by an immunodominant human T-cell receptor. J Biol Chem 2009; 284:27281-27289.
26. Storkus WJ, Howell DN, Salter RD, Dawson JR, Cresswell P. NK susceptibility varies inversely with target cell class I HLA antigen expression. J Immunol 1987; 138:1657-1659.
27. Purbhoo MA, Boulter JM, Price DA etal. The human CD8 coreceptor effects cytotoxic T cell activation and antigen sensitivity primarily by mediating complete phosphorylation of the T cell receptor zeta chain. J Biol Chem 2001; 276:32786-32792.
28. Bownds S, Tong-On P, Rosenberg SA, Parkhurst M. Induction of tumor-reactive cytotoxic T-lymphocytes using a peptide from NY-ESO-1 modified at the carboxy-terminus to enhance HLA-A2.1 binding affinity and stability in solution. J Immunother 2001; 24:1-9.
29. Schultz-Thater E, Noppen C, Gudat F etal. NY-ESO-1 tumour associated antigen is a cytoplasmic protein detectable by specific monoclonal antibodies in cell lines and clinical specimens. Br J Cancer 2000; 83:204-208.
30. Atanackovic D, Arfsten J, Cao Y etal. Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood 2007; 109:1103-1112.
31. Purbhoo MA, Sutton DH, Brewer JE etal. Quantifying and imaging NY-ESO-1/LAGE-1-derived epitopes on tumor cells using high affinity T cell receptors. J Immunol 2006; 176:7308-7316.
32. Kim KH, Choi JS, Kim IJ, Ku JL, Park JG. Promoter hypomethylation and reactivation of MAGE-A1 and MAGE-A3 genes in colorectal cancer cell lines and cancer tissues. World J Gastroenterol 2006; 12:5651-5657.
33. Marchand M, van Baren N, Weynants P etal. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999; 80:219-230.
34. Imro MA, Dellabona P, Manici S etal. Human melanoma cells transfected with the B7-2 co-stimulatory molecule induce tumor-specific CD8+ cytotoxic T lymphocytes in vitro. Hum Gene Ther 1998; 9:1335-1344.
35. Shimizu Y, DeMars R. Production of human cells expressing individual transferred HLA-A, -B, -C genes using an HLA-A, -B, -C null human cell line. J Immunol 1989; 142:3320-3328.
36. Celis E, Tsai V, Crimi C etal. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci USA 1994; 91:2105-2109.
37. Zhao Y, Bennett AD, Zheng Z etal. High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines. J Immunol 2007; 179:5845-5854.
38. Robbins PF, Li YF, El-Gamil M etal. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J Immunol 2008; 180:6116-6131.
39. Parry RV, Rumbley CA, Vandenberghe LH, June CH, Riley JL. CD28 and inducible costimulatory protein Src homology 2 binding domains show distinct regulation of phosphatidylinositol 3-kinase, Bcl-xL, and IL-2 expression in primary human CD4 T lymphocytes. J Immunol 2003; 171:166-174.
40. Lissina A, Ladell K, Skowera A etal. Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers. J Immunol Methods 2009; 340:11-24.
41. Wooldridge L, van den Berg HA, Glick M etal. Interaction between the CD8 coreceptor and major histocompatibility complex class I stabilizes T cell receptor-antigen complexes at the cell surface. J Biol Chem 2005; 280:27491-27501.
42. Sewell AK, Harcourt GC, Goulder PJ, Price DA, Phillips RE. Antagonism of cytotoxic T lymphocyte-mediated lysis by natural HIV-1 altered peptide ligands requires simultaneous presentation of agonist and antagonist peptides. Eur J Immunol 1997; 27:2323-2329.
43. Gotch F, Rothbard J, Howland K, Townsend A, McMichael A. Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2. Nature 1987; 326:881-882.
44. Roederer M, Nozzi JL, Nason MC. SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A 2011; 79:167-174.
45. Purbhoo MA, Li Y, Sutton DH etal. The HLA A*0201-restricted hTERT(540-548) peptide is not detected on tumor cells by a CTL clone or a high-affinity T-cell receptor. Mol Cancer Ther 2007; 6:2081-2091.
46. Gonzalez PA, Carreno LJ, Coombs D etal. T cell receptor binding kinetics required for T cell activation depend on the density of cognate ligand on the antigen-presenting cell. Proc Natl Acad Sci USA 2005; 102:4824-4829.
47. Leisegang M, Wilde S, Spranger S etal. MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors. J Clin Invest 2010; 120:3869-3877.
48. Schmid DA, Irving MB, Posevitz V etal. Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. J Immunol 2010; 184:4936-4946.
49. Price DA, Sewell AK, Dong T etal. Antigen-specific release of beta-chemokines by anti-HIV-1 cytotoxic T lymphocytes. Curr Biol 1998; 8:355-358.
50. Barrow C, Browning J, MacGregor D etal. Tumor antigen expression in melanoma varies according to antigen and stage. Clin Cancer Res 2006; 12:764-771.
51. Liddy N, Bossi G, Adams KJ etal. Monoclonal TCR-redirected tumor cell killing. Nat Med 2012; 18:980-987.
52. Betts MR, Exley B, Price DA etal. Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection. Proc Natl Acad Sci USA 2005; 102:4512-4517.
53. Makedonas G, Hutnick N, Haney D etal. Perforin and IL-2 upregulation define qualitative differences among highly functional virus-specific human CD8 T cells. PLOS Pathog 2010; 6:e1000798.
54. Genesca M, Rourke T, Li J etal. Live attenuated lentivirus infection elicits polyfunctional simian immunodeficiency virus Gag-specific CD8+ T cells with reduced apoptotic susceptibility in rhesus macaques that control virus replication after challenge with pathogenic SIVmac239. J Immunol 2007; 179:4732-4740.
55. Boaz MJ, Waters A, Murad S, Easterbrook PJ, Vyakarnam A. Presence of HIV-1 Gag-specific IFN-gamma+IL-2+ and CD28+IL-2+ CD4 T cell responses is associated with nonprogression in HIV-1 infection. J Immunol 2002; 169:6376-6385.
56. Kannanganat S, Ibegbu C, Chennareddi L, Robinson HL, Amara RR. Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells. J Virol 2007; 81:8468-8476.
57. Almeida JR, Sauce D, Price DA etal. Antigen sensitivity is a major determinant of CD8+ T-cell polyfunctionality and HIV-suppressive activity. Blood 2009; 113:6351-6360.
58. Darrah PA, Patel DT, De Luca PM etal. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007; 13:843-850.
59. Derrick SC, Yabe IM, Yang A, Morris SL. Vaccine-induced anti-tuberculosis protective immunity in mice correlates with the magnitude and quality of multifunctional CD4 T cells. Vaccine 2011; 29:2902-2909.
60. Betts MR, Nason MC, West SM etal. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006; 107:4781-4789.
61. Daucher M, Price DA, Brenchley JM etal. Virological outcome after structured interruption of antiretroviral therapy for human immunodeficiency virus infection is associated with the functional profile of virus-specific CD8+ T cells. J Virol 2008; 82:4102-4114.
62. Wilde S, Sommermeyer D, Leisegang M etal. Human antitumor CD8+ T cells producing Th1 polycytokines show superior antigen sensitivity and tumor recognition. J Immunol 2012; 189:598-605.
63. Appay V, Douek DC, Price DA. CD8+ T cell efficacy in vaccination and disease. Nat Med 2008; 14:623-628.
64. Irving M, Zoete V, Hebeisen M etal. Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness. J Biol Chem 2012; 287:23068-23078.
65. Hebeisen M, Baitsch L, Presotto D etal. SHP-1 phosphatase activity counteracts increased T cell receptor affinity. J Clin Invest 2013; 123:1044-1056.
66. McMahan RH, McWilliams JA, Jordan KR, Dow SW, Wilson DB, Slansky JE. Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines. J Clin Invest 2006; 116:2543-2551.
67. Zhong S, Malecek K, Johnson LA etal. T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy. Proc Natl Acad Sci USA 2013; 110:6973-6978.
68. Chervin AS, Stone JD, Soto CM etal. Design of T-cell receptor libraries with diverse binding properties to examine adoptive T-cell responses. Gene Ther 2013; 20:634-644.
69. Soto CM, Stone JD, Chervin AS etal. MHC-class I-restricted CD4 T cells: a nanomolar affinity TCR has improved anti-tumor efficacy in vivo compared to the micromolar wild-type TCR. Cancer Immunol Immunother 2013; 62:359-369.
70. King CG, Koehli S, Hausmann B, Schmaler M, Zehn D, Palmer E. T cell affinity regulates asymmetric division, effector cell differentiation, and tissue pathology. Immunity 2012; 37:709-720.
71. Ueno T, Tomiyama H, Fujiwara M, Oka S, Takiguchi M. Functionally impaired HIV-specific CD8 T cells show high affinity TCR-ligand interactions. J Immunol 2004; 173:5451-5457.
72. Thomas S, Xue SA, Bangham CR, Jakobsen BK, Morris EC, Stauss HJ. Human T cells expressing affinity-matured TCR display accelerated responses but fail to recognize low density of MHC-peptide antigen. Blood 2011; 118:319-329.
73. Boulter JM, Schmitz N, Sewell AK, Godkin AJ, Bachmann MF, Gallimore AM. Potent T cell agonism mediated by a very rapid TCR/pMHC interaction. Eur J Immunol 2007; 37:798-806.
74. Zhao Y, Zheng Z, Robbins PF, Khong HT, Rosenberg SA, Morgan RA. Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. J Immunol 2005; 174:4415-4423.
75. Chen JL, Morgan AJ, Stewart-Jones G etal. Ca2+ release from the endoplasmic reticulum of NY-ESO-1-specific T cells is modulated by the affinity of TCR and by the use of the CD8 coreceptor. J Immunol 2010; 184:1829-1839.
76. Kronig H, Hofer K, Conrad H etal. Allorestricted T lymphocytes with a high avidity T-cell receptor towards NY-ESO-1 have potent anti-tumor activity. Int J Cancer 2009; 125:649-655.
77. Cameron BJ, Gerry AB, Dukes J etal. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med 2013; 5:197ra103.
78. Linette GP, Stadtmauer EA, Maus MV etal. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 2013; 122:863-871.